// App-Quantinova.ai

S263 : THE SAFETY, PHARMACOKINETICS & PHARMACODYNAMIC EFFECTS OF IMR-687, A HIGHLY-SELECTIVE PDE9 INHIBITOR, IN ADULTS WITH SICKLE CELL DISEASE: PHASE-2A PLACEBO-CONTROLLED & OPEN-LABEL EXTENSION STUDIES

Researchers

Presenter

  • Biree Andemariam

Principal Investigators

  • Viktor Gordeuk

  • Jo Howard

  • Julie Kanter

  • Perla Eleftheriou

  • Shivan Pancham

  • Robert Hagar

  • Lois Clarke

  • Gershwin Blyden

  • Sanne Lugthart

  • Tim Mant

  • Henry Fok

  • Filipa Barroso

  • James Mason

  • Joseph Yen

  • Kenneth Attie

  • Joelle Lufkin

  • Rahul Ballal

Medical Centers

  • Gu-s and St Thoma- NHS, London, United Kingdom

  • University Hospital,Bristol,United Kingdom

  • White Medical Center,Temple,United States

  • Foundation for Sickle Cell Disease Research, Hollywood, FL

  • University of AL - Birmingham, AL, United States

  • Kings College London, London, United Kingdom

  • Imara,Boston,United States

  • University of Connecticut School of Medicine, Farmington, Connecticut, United States

  • Sandwell &amp

  • Pediatrics, Benioff Children's Hospital Oakland, Oakland, CA, United States,

  • Loretto Hospital,Chicago,United States

  • West Birmingham Hospital,Birmingham,United Kingdom

  • University of Illinois Health Chicago IL United States

  • The Royal Marsden Hospital, London, United Kingdom

  • Baylor Scott &amp

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Sickle cell anemia

Biomarkers

  • Volatile organic compounds

Drug/Treatment

  • Hydroxyurea

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Pharmacodynamics

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved